Eli Lilly Achieves Top Rankings in Pharmaceutical R&D Performance
STAT+: Eli Lilly tops prominent rankings on pharma R&D performance
Image: Stat
Eli Lilly has secured the top positions in a ranking by IDEA Pharma, showcasing its dominance in the pharmaceutical industry. The ranking evaluates companies based on innovation and invention, with Eli Lilly being the first to achieve No. 1 in both categories, reflecting its significant contributions to drug development and research.
- 01Eli Lilly ranked first in both innovation and invention categories of the IDEA Pharma index.
- 02The innovation category considers revenue from new products and drug approvals.
- 03The invention category assesses the number of drugs in development, clinical trials, and R&D investment.
- 04This is the first instance of a single company topping both categories in the ranking.
- 05IDEA Pharma is part of SAI MedPartners, a consultancy focused on pharmaceutical performance.
Advertisement
In-Article Ad
Eli Lilly has demonstrated its leadership in the pharmaceutical sector by topping both innovation and invention categories in the IDEA Pharma ranking. This ranking evaluates drug companies based on their ability to generate revenue from new products, secure new drug approvals, and achieve significant drug development milestones for innovation. For invention, criteria include the number of drugs in development, ongoing clinical trials, and research and development investment. Notably, this marks the first time a single company has achieved the No. 1 position in both categories, underscoring Eli Lilly's comprehensive strength in pharmaceutical research and development. IDEA Pharma is a consultancy based in the UK and part of SAI MedPartners.
Advertisement
In-Article Ad
Advertisement
In-Article Ad
Reader Poll
Do you think Eli Lilly's R&D performance will influence other pharmaceutical companies?
Connecting to poll...
More about Eli Lilly
Read the original article
Visit the source for the complete story.